Recent advancements in oral administration of insulin-loaded liposomal drug delivery systems for diabetes mellitus

[Display omitted] Diabetes is a chronic medical condition, which is characterised by high blood sugar level. Exogenous insulin is commonly administered subcutaneously for the management of diabetes. However, daily injections of insulin could result in poor patient compliance and various side-effects...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of pharmaceutics 2018-10, Vol.549 (1-2), p.201-217
Hauptverfasser: Wong, Chun Y., Al-Salami, Hani, Dass, Crispin R.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 217
container_issue 1-2
container_start_page 201
container_title International journal of pharmaceutics
container_volume 549
creator Wong, Chun Y.
Al-Salami, Hani
Dass, Crispin R.
description [Display omitted] Diabetes is a chronic medical condition, which is characterised by high blood sugar level. Exogenous insulin is commonly administered subcutaneously for the management of diabetes. However, daily injections of insulin could result in poor patient compliance and various side-effects. Although oral administration offers benefits, insulin is vulnerable to enzymatic degradation, chemical instability and poor gastrointestinal absorption. There is an absence of reviews on insulin-loaded liposomal drug carriers, despite that fact that liposomes have gained considerable attention recently for oral delivery of insulin. They demonstrate favourable characteristics, such as versatility, biocompatibility, protective effect against enzymatic degradation, and cell-specific targeting. In this review, we will explore the status quo for oral delivery of insulin-loaded liposomal formulations, followed by discussing the state of art of these vesicles. This review will provide a detailed overview on insulin-loaded conventional liposomes, and 7 types of current novel formulations. Lastly, the future direction for oral bioavailability enhancement and development of such nanoscale drug delivery systems will be discussed. Further optimisation in the drug entrapment efficiency and gastrointestinal absorption will be required to develop a clinically successful oral liposome-insulin formulation.
doi_str_mv 10.1016/j.ijpharm.2018.07.041
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2083724521</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0378517318305167</els_id><sourcerecordid>2083724521</sourcerecordid><originalsourceid>FETCH-LOGICAL-c365t-1987f9f5db0d5526423d1d73f24740e1380dcba15b1f570aab08d3ccd2ebf6703</originalsourceid><addsrcrecordid>eNqFkMFuFDEMhqOKim4XHgGUI5cZnMlkMntCqCpQqRJSBecokzglq8lkSTIr7duTaheunGzZv_3bHyHvGLQM2PBx3_r94ZdOoe2AjS3IFnp2RTZslLzhvRxekQ1wOTaCSX5DbnPeA8DQMf6a3HAAyTjsNiQ9ocGlUG2PejEYap6pX2hMeq7F4BefS9LFx1pztZPX2S_NHLVFS2d_iDmGKrVpfaYWZ3_EdKL5lAuGTF1M1Ho9YcFMA86zL2t-Q66dnjO-vcQt-fnl_sfdt-bx-9eHu8-PjeGDKA3bjdLtnLATWCG6oe-4ZVZy1_WyB2R8BGsmzcTEnJCg9QSj5cbYDic3SOBb8uG895Di7xVzUcFnU4_QC8Y1qw5GLrteVCRbIs5Sk2LOCZ06JB90OikG6gW32qsLbvWCW4FUFXede3-xWKeA9t_UX75V8OkswPro0WNS2XisoK1PaIqy0f_H4g_ALpZ2</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2083724521</pqid></control><display><type>article</type><title>Recent advancements in oral administration of insulin-loaded liposomal drug delivery systems for diabetes mellitus</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Wong, Chun Y. ; Al-Salami, Hani ; Dass, Crispin R.</creator><creatorcontrib>Wong, Chun Y. ; Al-Salami, Hani ; Dass, Crispin R.</creatorcontrib><description>[Display omitted] Diabetes is a chronic medical condition, which is characterised by high blood sugar level. Exogenous insulin is commonly administered subcutaneously for the management of diabetes. However, daily injections of insulin could result in poor patient compliance and various side-effects. Although oral administration offers benefits, insulin is vulnerable to enzymatic degradation, chemical instability and poor gastrointestinal absorption. There is an absence of reviews on insulin-loaded liposomal drug carriers, despite that fact that liposomes have gained considerable attention recently for oral delivery of insulin. They demonstrate favourable characteristics, such as versatility, biocompatibility, protective effect against enzymatic degradation, and cell-specific targeting. In this review, we will explore the status quo for oral delivery of insulin-loaded liposomal formulations, followed by discussing the state of art of these vesicles. This review will provide a detailed overview on insulin-loaded conventional liposomes, and 7 types of current novel formulations. Lastly, the future direction for oral bioavailability enhancement and development of such nanoscale drug delivery systems will be discussed. Further optimisation in the drug entrapment efficiency and gastrointestinal absorption will be required to develop a clinically successful oral liposome-insulin formulation.</description><identifier>ISSN: 0378-5173</identifier><identifier>EISSN: 1873-3476</identifier><identifier>DOI: 10.1016/j.ijpharm.2018.07.041</identifier><identifier>PMID: 30071309</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Administration, Oral ; Animals ; Biological Availability ; Cell-specific targeting ; Diabetes ; Diabetes Mellitus - drug therapy ; Drug Carriers - chemistry ; Drug Delivery Systems ; Humans ; Hypoglycemic Agents - administration &amp; dosage ; Hypoglycemic Agents - adverse effects ; Hypoglycemic Agents - pharmacokinetics ; Insulin ; Insulin - administration &amp; dosage ; Insulin - adverse effects ; Insulin - pharmacokinetics ; Liposome ; Liposomes ; Oral ; Surface coating</subject><ispartof>International journal of pharmaceutics, 2018-10, Vol.549 (1-2), p.201-217</ispartof><rights>2018 Elsevier B.V.</rights><rights>Copyright © 2018 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c365t-1987f9f5db0d5526423d1d73f24740e1380dcba15b1f570aab08d3ccd2ebf6703</citedby><cites>FETCH-LOGICAL-c365t-1987f9f5db0d5526423d1d73f24740e1380dcba15b1f570aab08d3ccd2ebf6703</cites><orcidid>0000-0003-0049-6969</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0378517318305167$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30071309$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wong, Chun Y.</creatorcontrib><creatorcontrib>Al-Salami, Hani</creatorcontrib><creatorcontrib>Dass, Crispin R.</creatorcontrib><title>Recent advancements in oral administration of insulin-loaded liposomal drug delivery systems for diabetes mellitus</title><title>International journal of pharmaceutics</title><addtitle>Int J Pharm</addtitle><description>[Display omitted] Diabetes is a chronic medical condition, which is characterised by high blood sugar level. Exogenous insulin is commonly administered subcutaneously for the management of diabetes. However, daily injections of insulin could result in poor patient compliance and various side-effects. Although oral administration offers benefits, insulin is vulnerable to enzymatic degradation, chemical instability and poor gastrointestinal absorption. There is an absence of reviews on insulin-loaded liposomal drug carriers, despite that fact that liposomes have gained considerable attention recently for oral delivery of insulin. They demonstrate favourable characteristics, such as versatility, biocompatibility, protective effect against enzymatic degradation, and cell-specific targeting. In this review, we will explore the status quo for oral delivery of insulin-loaded liposomal formulations, followed by discussing the state of art of these vesicles. This review will provide a detailed overview on insulin-loaded conventional liposomes, and 7 types of current novel formulations. Lastly, the future direction for oral bioavailability enhancement and development of such nanoscale drug delivery systems will be discussed. Further optimisation in the drug entrapment efficiency and gastrointestinal absorption will be required to develop a clinically successful oral liposome-insulin formulation.</description><subject>Administration, Oral</subject><subject>Animals</subject><subject>Biological Availability</subject><subject>Cell-specific targeting</subject><subject>Diabetes</subject><subject>Diabetes Mellitus - drug therapy</subject><subject>Drug Carriers - chemistry</subject><subject>Drug Delivery Systems</subject><subject>Humans</subject><subject>Hypoglycemic Agents - administration &amp; dosage</subject><subject>Hypoglycemic Agents - adverse effects</subject><subject>Hypoglycemic Agents - pharmacokinetics</subject><subject>Insulin</subject><subject>Insulin - administration &amp; dosage</subject><subject>Insulin - adverse effects</subject><subject>Insulin - pharmacokinetics</subject><subject>Liposome</subject><subject>Liposomes</subject><subject>Oral</subject><subject>Surface coating</subject><issn>0378-5173</issn><issn>1873-3476</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkMFuFDEMhqOKim4XHgGUI5cZnMlkMntCqCpQqRJSBecokzglq8lkSTIr7duTaheunGzZv_3bHyHvGLQM2PBx3_r94ZdOoe2AjS3IFnp2RTZslLzhvRxekQ1wOTaCSX5DbnPeA8DQMf6a3HAAyTjsNiQ9ocGlUG2PejEYap6pX2hMeq7F4BefS9LFx1pztZPX2S_NHLVFS2d_iDmGKrVpfaYWZ3_EdKL5lAuGTF1M1Ho9YcFMA86zL2t-Q66dnjO-vcQt-fnl_sfdt-bx-9eHu8-PjeGDKA3bjdLtnLATWCG6oe-4ZVZy1_WyB2R8BGsmzcTEnJCg9QSj5cbYDic3SOBb8uG895Di7xVzUcFnU4_QC8Y1qw5GLrteVCRbIs5Sk2LOCZ06JB90OikG6gW32qsLbvWCW4FUFXede3-xWKeA9t_UX75V8OkswPro0WNS2XisoK1PaIqy0f_H4g_ALpZ2</recordid><startdate>20181005</startdate><enddate>20181005</enddate><creator>Wong, Chun Y.</creator><creator>Al-Salami, Hani</creator><creator>Dass, Crispin R.</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0049-6969</orcidid></search><sort><creationdate>20181005</creationdate><title>Recent advancements in oral administration of insulin-loaded liposomal drug delivery systems for diabetes mellitus</title><author>Wong, Chun Y. ; Al-Salami, Hani ; Dass, Crispin R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c365t-1987f9f5db0d5526423d1d73f24740e1380dcba15b1f570aab08d3ccd2ebf6703</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Administration, Oral</topic><topic>Animals</topic><topic>Biological Availability</topic><topic>Cell-specific targeting</topic><topic>Diabetes</topic><topic>Diabetes Mellitus - drug therapy</topic><topic>Drug Carriers - chemistry</topic><topic>Drug Delivery Systems</topic><topic>Humans</topic><topic>Hypoglycemic Agents - administration &amp; dosage</topic><topic>Hypoglycemic Agents - adverse effects</topic><topic>Hypoglycemic Agents - pharmacokinetics</topic><topic>Insulin</topic><topic>Insulin - administration &amp; dosage</topic><topic>Insulin - adverse effects</topic><topic>Insulin - pharmacokinetics</topic><topic>Liposome</topic><topic>Liposomes</topic><topic>Oral</topic><topic>Surface coating</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wong, Chun Y.</creatorcontrib><creatorcontrib>Al-Salami, Hani</creatorcontrib><creatorcontrib>Dass, Crispin R.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of pharmaceutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wong, Chun Y.</au><au>Al-Salami, Hani</au><au>Dass, Crispin R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Recent advancements in oral administration of insulin-loaded liposomal drug delivery systems for diabetes mellitus</atitle><jtitle>International journal of pharmaceutics</jtitle><addtitle>Int J Pharm</addtitle><date>2018-10-05</date><risdate>2018</risdate><volume>549</volume><issue>1-2</issue><spage>201</spage><epage>217</epage><pages>201-217</pages><issn>0378-5173</issn><eissn>1873-3476</eissn><abstract>[Display omitted] Diabetes is a chronic medical condition, which is characterised by high blood sugar level. Exogenous insulin is commonly administered subcutaneously for the management of diabetes. However, daily injections of insulin could result in poor patient compliance and various side-effects. Although oral administration offers benefits, insulin is vulnerable to enzymatic degradation, chemical instability and poor gastrointestinal absorption. There is an absence of reviews on insulin-loaded liposomal drug carriers, despite that fact that liposomes have gained considerable attention recently for oral delivery of insulin. They demonstrate favourable characteristics, such as versatility, biocompatibility, protective effect against enzymatic degradation, and cell-specific targeting. In this review, we will explore the status quo for oral delivery of insulin-loaded liposomal formulations, followed by discussing the state of art of these vesicles. This review will provide a detailed overview on insulin-loaded conventional liposomes, and 7 types of current novel formulations. Lastly, the future direction for oral bioavailability enhancement and development of such nanoscale drug delivery systems will be discussed. Further optimisation in the drug entrapment efficiency and gastrointestinal absorption will be required to develop a clinically successful oral liposome-insulin formulation.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>30071309</pmid><doi>10.1016/j.ijpharm.2018.07.041</doi><tpages>17</tpages><orcidid>https://orcid.org/0000-0003-0049-6969</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0378-5173
ispartof International journal of pharmaceutics, 2018-10, Vol.549 (1-2), p.201-217
issn 0378-5173
1873-3476
language eng
recordid cdi_proquest_miscellaneous_2083724521
source MEDLINE; Elsevier ScienceDirect Journals
subjects Administration, Oral
Animals
Biological Availability
Cell-specific targeting
Diabetes
Diabetes Mellitus - drug therapy
Drug Carriers - chemistry
Drug Delivery Systems
Humans
Hypoglycemic Agents - administration & dosage
Hypoglycemic Agents - adverse effects
Hypoglycemic Agents - pharmacokinetics
Insulin
Insulin - administration & dosage
Insulin - adverse effects
Insulin - pharmacokinetics
Liposome
Liposomes
Oral
Surface coating
title Recent advancements in oral administration of insulin-loaded liposomal drug delivery systems for diabetes mellitus
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T09%3A50%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Recent%20advancements%20in%20oral%20administration%20of%20insulin-loaded%20liposomal%20drug%20delivery%20systems%20for%20diabetes%20mellitus&rft.jtitle=International%20journal%20of%20pharmaceutics&rft.au=Wong,%20Chun%20Y.&rft.date=2018-10-05&rft.volume=549&rft.issue=1-2&rft.spage=201&rft.epage=217&rft.pages=201-217&rft.issn=0378-5173&rft.eissn=1873-3476&rft_id=info:doi/10.1016/j.ijpharm.2018.07.041&rft_dat=%3Cproquest_cross%3E2083724521%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2083724521&rft_id=info:pmid/30071309&rft_els_id=S0378517318305167&rfr_iscdi=true